Pharmacologic therapy of polycystic ovary syndrome

Clinical Obstetrics and Gynecology

Volumn 50, Issue 1, 2007, Pages 244-254

  Dronavalli, Suma ^a   Ehrmann, David A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Hirsutism; Hyperandrogenism; Insulin resistance; Oligomenorrhea; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIANDROGEN; CYANOCOBALAMIN; CYPROTERONE ACETATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; FLUTAMIDE; GESTAGEN; INSULIN; KELNOR; LOOVRAL; MEDROXYPROGESTERONE ACETATE; METFORMIN; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; PROGESTERONE; PROGESTERONE DERIVATIVE; ROSIGLITAZONE; SPIRONOLACTONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YAZ; ZOVIA;

ADD ON THERAPY; AMENORRHEA; ANOREXIA; ARTICLE; BLOATING; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG TARGETING; DYSPLASIA; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; GLUCOSE TOLERANCE; GROWTH RETARDATION; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIVER TOXICITY; MENSTRUAL CYCLE; METABOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOMENORRHEA; OPTIMAL DRUG DOSE; OVARY POLYCYSTIC DISEASE; PROTECTION; REGULATORY MECHANISM; SIDE EFFECT; SYMPTOMATOLOGY; TASTE DISORDER; WEIGHT GAIN;

AMENORRHEA; CONTRACEPTIVES, ORAL, HORMONAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERANDROGENISM; METFORMIN; OLIGOMENORRHEA; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 33847150903     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31802f35a0     Document Type: Article

References (41)

1. Ehrmann DA, Rychlik D. Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med. 2003;21:277-283.
2. Korytkowski MT, Mokan M, Horwitz MJ, et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:3327-3334.
3. Leblanc ES, Laws A. Benefits and risks of third-generation oral contraceptives. J Gen Intern Med. 1999;14:625-632.
4. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817-2823.
5. Cibula D, Sindelka G, Hill M, et al. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod. 2002;17:76-82.
6. Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab. 1997;82:3074-3077.
7. Lakhani K, Prelevic GM, Seifalian AM, et al. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol. 2004;24:613-621.
8. Cibula D, Hill M, Fanta M, et al. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod. 2001;16:940-944.
9. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349:1443-1450.
10. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006;85:436-440.
11. Pulido J, Salazar M. Changes in insulin sensitivity, secretion, and glucose effectiveness during menstrual cycle. Arch Med Res. 1999;30:19-22.
12. Palep-Singh M, Mook K, Barth J, et al. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care. 2004;30:163-165.
13. Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005;28:49-53.
14. Morin-Papunen LC, Koivunen RM, Ruokonen A, et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69:691-696.
15. Cibula D, Fanta M, Vrbikova J, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod. 2005;20:180-184.
16. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000;73:1149-1154.
17. Lord J, Flight I, Norman R. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2006.
18. Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:524-530.
19. Morin-Papunen L, Vauhkonen I, Koivunen R, et al. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003;88:148-156.
20. Maciel GA, Soares Junior JM, Alves da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril. 2004;81:355-360.
21. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
22. Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23:1227-1231.
23. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiolcyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002;17:1729-1737.
24. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1360-1365.
25. Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod. 2003;18:1210-1218.
26. Seto-Young D, Paliou M, Schlosser J, et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab. 2005;90:6099-6105.
27. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:3299-3306.
28. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-2116.
29. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626-1632.
30. Belli SH, Graffigna MN, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril. 2004;81:624-629.
31. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab. 2004;90:60-65.
32. Yilmaz M, Karakoc A, Toruner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol. 2005;21:154-160.
33. Rautio K, Tapanainen JS, Ruokonen A, et al. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod. 2006;21:1400-1407.
34. Brettenthaler N, De Geyter C, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:3835-3840.
35. Garmes HM, Tambascia MA, Zantut-Wittmann DE. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol. 2005;21:317-323.
36. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
37. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-1554.
38. DeLeo V, laMarca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24:633-667.
39. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82:893-902.
40. Glueck CJ, Moreira A, Goldenberg N, et al. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod. 2003;18:1618-1625.
41. Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod. 2006;21:121-128.